176 related articles for article (PubMed ID: 28427156)
1. The effects of DLEU1 gene expression in Burkitt lymphoma (BL): potential mechanism of chemoimmunotherapy resistance in BL.
Lee S; Luo W; Shah T; Yin C; O'Connell T; Chung TH; Perkins SL; Miles RR; Ayello J; Morris E; Harrison L; van de Ven C; Cairo MS
Oncotarget; 2017 Apr; 8(17):27839-27853. PubMed ID: 28427156
[TBL] [Abstract][Full Text] [Related]
2. Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia (pre-B-ALL): potential targeted therapy in patients with poor risk CD20(+) BL and pre-B-ALL.
Awasthi A; Ayello J; Van de Ven C; Elmacken M; Sabulski A; Barth MJ; Czuczman MS; Islam H; Klein C; Cairo MS
Br J Haematol; 2015 Dec; 171(5):763-75. PubMed ID: 26471982
[TBL] [Abstract][Full Text] [Related]
3. An increased frequency of 13q deletions detected by fluorescence in situ hybridization and its impact on survival in children and adolescents with Burkitt lymphoma: results from the Children's Oncology Group study CCG-5961.
Nelson M; Perkins SL; Dave BJ; Coccia PF; Bridge JA; Lyden ER; Heerema NA; Lones MA; Harrison L; Cairo MS; Sanger WG
Br J Haematol; 2010 Feb; 148(4):600-10. PubMed ID: 19895612
[TBL] [Abstract][Full Text] [Related]
4. Novel cytokine-antibody fusion protein, N-820, to enhance the functions of ex vivo expanded natural killer cells against Burkitt lymphoma.
Chu Y; Nayyar G; Kham Su N; Rosenblum JM; Soon-Shiong P; Lee J; Safrit JT; Barth M; Lee D; Cairo MS
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33109629
[TBL] [Abstract][Full Text] [Related]
5. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.
Thomas DA; Faderl S; O'Brien S; Bueso-Ramos C; Cortes J; Garcia-Manero G; Giles FJ; Verstovsek S; Wierda WG; Pierce SA; Shan J; Brandt M; Hagemeister FB; Keating MJ; Cabanillas F; Kantarjian H
Cancer; 2006 Apr; 106(7):1569-80. PubMed ID: 16502413
[TBL] [Abstract][Full Text] [Related]
6. Midostaurin potentiates rituximab antitumor activity in Burkitt's lymphoma by inducing apoptosis.
Ge X; Chen J; Li L; Ding P; Wang Q; Zhang W; Li L; Lv X; Zhou D; Jiang Z; Zeng H; Xu Y; Hou Y; Hu W
Cell Death Dis; 2018 Dec; 10(1):8. PubMed ID: 30584254
[TBL] [Abstract][Full Text] [Related]
7. Triptolide induces mitochondria-mediated apoptosis of Burkitt's lymphoma cell via deacetylation of GSK-3β by increased SIRT3 expression.
Kong J; Wang L; Ren L; Yan Y; Cheng Y; Huang Z; Shen F
Toxicol Appl Pharmacol; 2018 Mar; 342():1-13. PubMed ID: 29407771
[TBL] [Abstract][Full Text] [Related]
8. CD49d and CD49e induce cell adhesion-mediated drug resistance through the nuclear factor-κB pathway in Burkitt lymphoma.
Takeda T; Tsubak M; Genno S; Matsuda T; Yamamoto Y; Ueda E; Imano M; Satou T; Nishida S
J Physiol Pharmacol; 2020 Aug; 71(4):. PubMed ID: 33214335
[TBL] [Abstract][Full Text] [Related]
9. CD95-mediated apoptosis in Burkitt's lymphoma B-cells is associated with Pim-1 down-regulation.
Matou-Nasri S; Rabhan Z; Al-Baijan H; Al-Eidi H; Yahya WB; Al Abdulrahman A; Almobadel N; Alsubeai M; Al Ghamdi S; Alaskar A; AlBalwi M; Alzahrani M; Alabdulkareem I
Biochim Biophys Acta Mol Basis Dis; 2017 Jan; 1863(1):239-252. PubMed ID: 27641442
[TBL] [Abstract][Full Text] [Related]
10. Shikonin exerts antitumor activity in Burkitt's lymphoma by inhibiting C-MYC and PI3K/AKT/mTOR pathway and acts synergistically with doxorubicin.
Ni F; Huang X; Chen Z; Qian W; Tong X
Sci Rep; 2018 Feb; 8(1):3317. PubMed ID: 29463831
[TBL] [Abstract][Full Text] [Related]
11. BI6727, a polo-like kinase 1 inhibitor with promising efficacy on Burkitt lymphoma cells.
Chen E; Pei R
J Int Med Res; 2020 May; 48(5):300060520926093. PubMed ID: 32468878
[TBL] [Abstract][Full Text] [Related]
12. Endemic Burkitt lymphoma avatar mouse models for exploring inter-patient tumor variation and testing targeted therapies.
Saikumar Lakshmi P; Oduor CI; Forconi CS; M'Bana V; Bly C; Gerstein RM; Otieno JA; Ong'echa JM; Münz C; Luftig MA; Brehm MA; Bailey JA; Moormann AM
Life Sci Alliance; 2023 May; 6(5):. PubMed ID: 36878637
[TBL] [Abstract][Full Text] [Related]
13. Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas.
Fayad L; Thomas D; Romaguera J
Clin Lymphoma Myeloma; 2007 Dec; 8 Suppl 2():S57-62. PubMed ID: 18284717
[TBL] [Abstract][Full Text] [Related]
14. Rituximab is highly effective in children and adolescents with Burkitt lymphoma in Risk Groups R2 to R4.
Zhen Z; Zhu J; Wang J; Lu S; Sun F; Huang J; Sun X
Pediatr Hematol Oncol; 2020 Sep; 37(6):489-499. PubMed ID: 32364412
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma.
Giulino-Roth L; van Besien HJ; Dalton T; Totonchy JE; Rodina A; Taldone T; Bolaender A; Erdjument-Bromage H; Sadek J; Chadburn A; Barth MJ; Dela Cruz FS; Rainey A; Kung AL; Chiosis G; Cesarman E
Mol Cancer Ther; 2017 Sep; 16(9):1779-1790. PubMed ID: 28619753
[TBL] [Abstract][Full Text] [Related]
16. Gastric Burkitt lymphoma is a distinct subtype that has superior outcomes to other types of Burkitt lymphoma/leukemia.
Park YH; Kim WS; Kang HJ; Na II; Ryoo BY; Yang SH; Lee SS; Uhm JE; Kim K; Jung CW; Park K; Ko YH
Ann Hematol; 2006 May; 85(5):285-90. PubMed ID: 16518604
[TBL] [Abstract][Full Text] [Related]
17. Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma.
Richter-Larrea JA; Robles EF; Fresquet V; Beltran E; Rullan AJ; Agirre X; Calasanz MJ; Panizo C; Richter JA; Hernandez JM; Roman-Gomez J; Prosper F; Martinez-Climent JA
Blood; 2010 Oct; 116(14):2531-42. PubMed ID: 20570860
[TBL] [Abstract][Full Text] [Related]
18. DLC-1 as a modulator of proliferation, apoptosis and migration in Burkitt's lymphoma cells.
Feng M; Huang B; Du Z; Xu X; Chen Z
Mol Biol Rep; 2011 Mar; 38(3):1915-20. PubMed ID: 20882354
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic upregulation of lncRNAs at 13q14.3 in leukemia is linked to the In Cis downregulation of a gene cluster that targets NF-kB.
Garding A; Bhattacharya N; Claus R; Ruppel M; Tschuch C; Filarsky K; Idler I; Zucknick M; Caudron-Herger M; Oakes C; Fleig V; Keklikoglou I; Allegra D; Serra L; Thakurela S; Tiwari V; Weichenhan D; Benner A; Radlwimmer B; Zentgraf H; Wiemann S; Rippe K; Plass C; Döhner H; Lichter P; Stilgenbauer S; Mertens D
PLoS Genet; 2013 Apr; 9(4):e1003373. PubMed ID: 23593011
[TBL] [Abstract][Full Text] [Related]
20. Long non-coding RNA deleted in lymphocytic leukaemia 1 promotes hepatocellular carcinoma progression by sponging miR-133a to regulate IGF-1R expression.
Zhang W; Liu S; Liu K; Liu Y
J Cell Mol Med; 2019 Aug; 23(8):5154-5164. PubMed ID: 31207081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
